

WEBINAR SERIES INVITATION

ICLUSIG® (ponatinib): Rethink Your Approach to Treatment

FEATURING:

Moshe Y. Levy, MD
Director, Hematology Malignancy Research
Baylor
Dallas, TX

DATE:

Tuesday, April 28, 2020

TIME:

7:00 PM CST

RSVP:

Register here:

https://event.webcasts.com/starthere.jsp?ei=1301916&tp_key=7d051d222b

RSVP by:

04/24/2020

FEATURING:

Allison S. Morin, MSN
Nurse Practitioner
Northwestern Medicine
Chicago, IL

DATE:

Wednesday, May 6, 2020

TIME:

7:00 PM CST

RSVP:

Register here:

https://event.webcasts.com/starthere.jsp?ei=1301957&tp_key=ff6d783af9

RSVP by:

05/04/2020

FEATURING:

James K. McCloskey, MD
Interim Chief of Leukemia
John Theurer Cancer Center
Hackensack, NJ

DATE:

Wednesday, May 13, 2020

TIME:

8:00 PM EST

RSVP:

Register here:

https://event.webcasts.com/starthere.jsp?ei=1301962&tp_key=9ed53b0e6e

RSVP by:

05/11/2020

Please [click here](#) for accompanying full Prescribing Information, including Boxed Warning.

This program is developed and sponsored by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The speakers will present information that complies with the US Food and Drug Administration's (FDA) regulations and guidelines.



ONCOLOGY

All trademarks are the property of their respective owners.
©2020 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
All rights reserved. 4/20 USO-ICL-0030


ICLUSIG[®]
(ponatinib) tablets
45 mg, 15 mg